Pharmacogenetic and Pharmacokinetic Aspects of the Response to Chemotherapy Induction Using Docetaxel, Cisplatin and 5-Fluorouracile (TPF)in ORL Cancers

Inclusion Criteria:

- Squamous cell carcinoma originating in the mouth, oropharynx, larynx or hypopharynx
has been histologically documented.

- The disease is at one of the following UICC 2002 stages, regardless of ganglion
status: T3 MO or T4 MO

- Treatment via chemotherapy, radiotherapy or surgery (except for the diagnostic
biopsy) has not started

- The pluridisciplinary committee as ruled out surgical options for technical or
functional reasons

- Absence of distant metastases

- OMS general health status between 0 and 2

- Patient has given informed consent

- Patient is affiliated with a social security system

Exclusion Criteria:

- Undifferentiated squamous cell carcinomas in the nasopharynx (UCNT)

- Another cancer priorly treated with one of the following chemotherapies: Docetaxel,
Cisplatin, 5-Fluorouracile

- Creatininemia > 2 mg/dl and/or creatinine clearance < 60ml/min

- Patient under guardianship

- Presence of another severe pathology including:

- severe or chronic cardiac, renal and/or hepatic insufficiencies

- severe medullary hypoplasia

- severe autoimmune disease

- psychosis or senility